MarketBebtelovimab
Company Profile

Bebtelovimab

Bebtelovimab is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19.

Medical uses
Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022, == History ==
History
Bebtelovimab emerged from a collaboration between Eli Lilly and AbCellera. Bebtelovimab was discovered by AbCellera and the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. == Society and culture ==
Society and culture
Legal status Bebtelovimab was authorized for medical use in the United States via an emergency use authorization in February 2022. , bebtelovimab is not authorized for emergency use in the US because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. == References ==
tickerdossier.comtickerdossier.substack.com